The Latest Analyst Ratings For Marinus Pharma
Portfolio Pulse from Benzinga Insights
Marinus Pharma (NASDAQ:MRNS) received mixed analyst ratings over the past three months, with a total of 7 analysts providing insights. The ratings ranged from bullish to indifferent, with no bearish views. The 12-month price targets suggest a significant potential upside, with an average target of $20.71, a high of $28.00, and a low of $3.00. This marks a 25.52% increase from the previous average target of $16.50. Analysts' actions included maintaining, lowering, and raising ratings and price targets, reflecting their adaptation to market conditions and company performance.
April 16, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marinus Pharma received mixed ratings from analysts, with an updated average 12-month price target of $20.71, indicating a potential upside from current levels.
The mixed analyst ratings with a significant potential upside in the price target suggest a positive outlook for MRNS in the short term. The increase in the average price target to $20.71 from $16.50 reflects analysts' optimism about the company's future performance. This optimism, combined with the detailed analysis of the company's financial health and market position, indicates a likely positive impact on MRNS's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100